Incyte’s Povorcitinib Hits Primary Endpoints in Phase 3 HS Studies
Povorcitinib (Incyte) produced statistically significant results for primary endpoints in two Phase 3 Hidradenitis Suppurativa (HS) trials, Incyte reports in a news release.
Category: Hidradenitis Suppurativa